2017-10-17 13:06:38 UTC

How Will Translational Advances in Pediatric IBD Affect Practices?

Oct. 17, 2017

Dr. Rosen will discuss how new findings can make a difference for pediatric IBD patients at the Crohn’s & Colitis Congress.

In the past year there have been tremendous translational advances in our understanding of the biology of pediatric inflammatory bowel disease (IBD) that will have important implications for how to assess IBD phenotype, predict treatment response and stratify therapy for  patients. 

Hear Michael Rosen, MD, MSCI, Cincinnati Children's Hospital Medical Center, as he critically assesses these studies and discusses how these findings can be applied to clinical practice to make a difference for pediatric patients. Register for AGA and the Crohn's & Colitis Foundation's Crohn's & Colitis Congress™, Jan. 18-20, 2018, in Las Vegas and add-on the Pre-Congress Workshop: Cutting-Edge Pediatric IBD to attend Dr. Rosen's session Translational Advances in Pediatric IBD – How Will It Affect My Practice? 

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Healing of Tonsillar Crohn’s Disease With Infliximab

Oct. 22, 2017

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Oct. 22, 2017

We investigated whether serum trough levels of vedolizumab, during the induction phase can determine whether patients need additional doses within 6 months.